For laboratory and research use only. Not for human consumption.
Comparison

Thymosin Alpha-1 vs Thymulin

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

Thymosin Alpha-1

Also: Ta1, Zadaxin

Clinical Trials

Thymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in a number of countries, including China and Italy, mainly for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with more than 30 trials and over 11,000 subjects.

ImmuneHuman Trials
Thymulin

Also: Facteur thymique serique, FTS

Preclinical

Thymulin is a tiny nine-amino-acid hormone made by the epithelial cells of the thymus, first described in the 1970s as facteur thymique serique (FTS). It only works when bound to one zinc atom, which makes it an oddly neat marker of zinc status. It plays a part in training T cells, and animal work suggests anti-inflammatory and pain-reducing effects. It is sold online for immune support and hair loss, but there are no modern human trials of giving it, and the hair claims rest on lab dishes and a sponsor-linked cosmetic study.

ImmunePreclinical

Key Comparison Insights

  • Both peptides belong to the Immune category, suggesting similar primary applications.
  • Thymosin Alpha-1 has stronger research evidence (Human Trials) compared to Thymulin (Preclinical).

Detailed Comparison

AttributeThymosin Alpha-1Thymulin
CategoryImmuneImmune
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionThymosin alpha-1 works as an immune modulator rather than a stimulant, meaning it tries to rebalance the immune system rather than simply rev it up. It signals through toll-like receptors, particularly TLR9 and TLR2, on dendritic cells, which are the immune system's messengers. That signaling pushes naive T cells toward a Th1 (pathogen-fighting) profile, boosts natural killer cell activity, and improves antibody responses. At the same time it can promote regulatory T cells via the IDO pathway, which is why it is described as restoring balance: it can both wake up a sluggish immune response and dampen a dangerously overactive one.Thymulin (sequence Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) binds zinc in a 1:1 ratio, and only the zinc-bound form has biological activity. It promotes T cell differentiation inside and outside the thymus and influences T cell subsets and cytokine production. Its levels fall with age as the thymus shrinks, and fall with zinc deficiency. Researchers led by Goya and Reggiani have described a two-way link with the pituitary: thymulin seems to affect pituitary hormone release, and pituitary hormones affect thymulin secretion. In rodent models, thymulin and a synthetic analogue reduced inflammation and pain signalling, partly by dampening pro-inflammatory cytokines. How much of this applies to a peptide injected into a healthy adult is unknown.
Common Dosing
1.6 mg twice weekly
2-3x weekly
No established dose
Unknown
AdministrationSubcutaneous injectionSold for subcutaneous injection or topical use; neither route has been tested in controlled human trials
Typical Duration6-12 months for hepatitisUnknown; no human trials to guide duration
Best Time to TakeMorningNo evidence-based timing
Possible Side Effects
May vary by individual
  • Injection site reactions (most common)
  • Mild fatigue
  • Headache
  • Rare allergic reactions
  • Contraindicated in immunosuppressed transplant patients
  • No human safety data for administered thymulin
  • Injection site reactions (expected with any injected peptide)
  • Theoretical immune effects in people with autoimmune disease
  • Unknown purity and contamination risk in unregulated products
  • Topical products: possible scalp irritation
Research SummaryThis is one of the few peptides on this list with serious human trial data, but the results are mixed and worth reading honestly. Thymosin alpha-1 is approved abroad and widely used for chronic hepatitis B, often alongside interferon, and decades of use give it a strong safety record across more than 30 trials and over 11,000 subjects. The standout area is sepsis, and the story there is a cautionary tale: the earlier ETASS trial (Critical Care, 2013) hinted at lower 28-day mortality (26 percent versus 35 percent), but the much larger, better-designed TESTS phase 3 trial (BMJ, 2025, 1,106 patients at 22 Chinese centers, double-blind and placebo-controlled, dosed under the skin every 12 hours for 7 days) found no mortality benefit at all (23.4 versus 24.1 percent). It has also been studied as an add-on in certain cancers and in vaccine response, with weaker evidence. The honest summary: real drug, good safety, proven in hepatitis B, but several of its most-hyped uses did not survive a rigorous trial.Most of what is solid here is basic physiology. Dardenne and Pleau (1994) reviewed the zinc dependence: no zinc, no activity. Prasad and colleagues (JCI, 1988) showed that serum thymulin activity dropped in people made mildly zinc deficient by diet and came back with zinc supplementation, alongside shifts in T cell ratios and IL-2, so thymulin is a useful readout of zinc status. Reviews by Reggiani, Goya and colleagues (2012-2014) summarize anti-inflammatory and analgesic effects in rodents and gene therapy work in athymic mice, but frame human use as a future goal. On hair: Meier and colleagues (J Invest Dermatol, 2012) found a low dose of thymulin increased hair shaft growth in organ-cultured human scalp follicles, a dish result rather than a clinical one. A 2013 cosmetic study of a thymus peptide serum and shampoo reported less hair shedding on pull tests, but it was tied to the product maker and not a controlled regrowth trial. There are no controlled trials of injected or topical thymulin for immunity, aging or hair in people, and no human safety data. If you have low zinc, fixing that is better proven than adding the peptide.

Frequently Asked Questions: Thymosin Alpha-1 vs Thymulin

What is the difference between Thymosin Alpha-1 and Thymulin?

Thymosin Alpha-1 is a immune peptide that thymosin alpha-1 (sold as zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. unlike most peptides in this space, it is a real, approved drug in a number of countries, including china and italy, mainly for chronic hepatitis b and as an immune booster, though it has never been approved by the fda in the united states. it has one of the larger human evidence bases of any peptide here, with more than 30 trials and over 11,000 subjects. Thymulin is a immune peptide that thymulin is a tiny nine-amino-acid hormone made by the epithelial cells of the thymus, first described in the 1970s as facteur thymique serique (fts). it only works when bound to one zinc atom, which makes it an oddly neat marker of zinc status. it plays a part in training t cells, and animal work suggests anti-inflammatory and pain-reducing effects. it is sold online for immune support and hair loss, but there are no modern human trials of giving it, and the hair claims rest on lab dishes and a sponsor-linked cosmetic study. The main differences lie in their mechanisms of action and clinical applications.

Which is better, Thymosin Alpha-1 or Thymulin?

Neither is universally "better" - the choice depends on your specific goals. Thymosin Alpha-1 is typically used for immune purposes, while Thymulin is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can Thymosin Alpha-1 and Thymulin be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Alpha-1 and Thymulin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles